

Free Radical Scavenging, Enzyme Inhibitory and Anti-*Staphylococcus aureus* Properties of the Fruiting Bodies of *Ganoderma lucidum*, Lingzhi Mushroom

Md. Moyan Uddin PK^{1,2,3#}, Mohammad Sayful Islam^{4,5*#}, Shariful Haque⁶, Lutfa Akther⁷,
Rumana Pervin²

¹Institute of Biological Science, University of Rajshahi, Rajshahi, Bangladesh

²Department of Biochemistry & Molecular Biology, University of Rajshahi, Rajshahi, Bangladesh

³School of Science, Independent University of Bangladesh, Dhaka, Bangladesh

⁴Department of Pharmacy, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh

⁵Department of Biochemistry, Asahikawa Medical University, Hokkaido, Japan

⁶Department of Pharmacy, Pabna University of Science and Technology, Pabna, Bangladesh

⁷RHSTEP, Dhaka Medical College Hospital, Dhaka, Bangladesh

Email: *sayful@asahikawa-med.ac.jp

How to cite this paper: Md. Moyan Uddin PK, Islam, M.S., Haque, S., Akther, L. and Pervin, R. (2021) Free Radical Scavenging, Enzyme Inhibitory and Anti-*Staphylococcus aureus* Properties of the Fruiting Bodies of *Ganoderma lucidum*, Lingzhi Mushroom. *Pharmacology & Pharmacy*, 12, 73-84.
<https://doi.org/10.4236/pp.2021.123007>

Received: January 24, 2021

Accepted: March 19, 2021

Published: March 22, 2021

Copyright © 2021 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).
<http://creativecommons.org/licenses/by/4.0/>



Open Access

Abstract

The current study evaluated the antioxidant, α -amylase inhibitory and anti-*Staphylococcus aureus* activities of the fruiting bodies of *Ganoderma lucidum*. Methanolic extract of *G. lucidum* (MEGL) was investigated for its *in vitro* antioxidant activity using 1,1-diphenyl 2-picrylhydrazyl (DPPH) assay and EC₅₀ value was determined. α -Amylase inhibitory and anti-*S. aureus* activities were carried out by conventional methods. The mushroom extract showed maximum free radical scavenging activity at a dose of 500 μ g/mL with EC₅₀ value of 22.1399 μ g/mL. EC₅₀ value for the inhibition of α -amylase activity was found 22.6011 μ g/mL. *G. lucidum* extracts exhibited a concentration-dependent Anti-*S. aureus* activity. The vast differences of this inhibition between lower and higher doses were assessed significantly ($p < 0.05$). This study shows that the fruiting body of *G. lucidum* has moderate antioxidant, α -amylase inhibitory, and anti-*S. aureus* activities. Thus this mushroom may be the alternative plant source for the antioxidant, anti-diabetic and antibacterial agents and further *in vivo* studies and isolation of bioactive compounds are required.

#Equal contributions. *Corresponding author.

Keywords

Ganoderma lucidum, Mushroom, Antioxidant Activity, Enzyme Inhibitory Activity, Anti-*Staphylococcus aureus* Activities

1. Introduction

Medicinal mushrooms have a very long history of traditional uses and are attracting much attention in the nutraceuticals and pharmaceuticals field. Mushrooms have become impressive as functional foods for their physiologically beneficial bioactive compounds [1]. A number of secondary metabolites were discovered from the fungi kingdom with high therapeutic values like antioxidant, anti-diabetic, antimicrobial, anti-inflammatory, and anticancer properties [2] [3] [4] [5] [6]. Important bioactive components reported from the various edible and medicinal mushrooms are polysaccharides, proteins, fatty acids, sterols, polyphenolic compounds, vitamins, and minerals [7] [8] [9] [10]. Several studies revealed that these active components of mushrooms have a favorable impact on human health through the modulating of the immune system, and by their antioxidant and anti-inflammatory activities [1] [2] [3]. Thus mushrooms can be used as an alternative for prevention as well as treatment of various diseases of mankind.

Ganoderma lucidum, is a wood degrading basidiomycete belonging to the family of Ganodermaceae of Polyporales. It is commonly named “Lingzhi” in Chiana and “Reishi” in Japan [11]. *Ganoderma* is one of the most common medicinal mushrooms used traditionally for the longevity and promotion of human health [12] [13] [14]. It is considered a popular folk medicine for the treatment of general disorders, arthritis, hepatitis, bronchitis, dermatological disorders and to boost up the immune functions by indigenous peoples worldwide [15]. Several bioactive compounds have been isolated from the *G. lucidum* among them polysaccharides, triterpenes, peptidoglycans, steroids, and nucleotides are the important physiologically active constituents [16]. It has been known that *G. lucidum* has exhibited diverse pharmacological effects which are antioxidative [17], antiobesity [18], anticancer [19], antihepatic damage [20], neuroprotective [21], cardioprotective [22], antidiabetic [23], antiproliferative, and cytotoxicity activities [24].

Recently, multi-drug resistant bacterial strains represent a serious healthcare problem in the treatment of infectious diseases [25]. On the other hand, diabetes is a rapidly growing disease and considered one of the leading causes of morbidity and mortality worldwide [26]. Moreover, free radicals which are highly reactive to DNA, protein, membrane lipids [27], play a role in a number of human diseases including cancers, diabetes, atherosclerosis, and various types of neurodegenerative disorders [28]. So, it is necessary to search the new bioactive agents for the effective treatment of these diseases. In this case, medicinal mushrooms have triggered a significant research interest to develop novel compounds for the treatment of various diseases.

Fruiting body is the main medicinal part of *Ganoderma* mushrooms but spore

and mycelium also retain their medicinal values. In this study, we evaluated the free radical scavenging, α -amylase inhibitory, and anti-*S. aureus* properties of the methanolic extract of the fruiting bodies of *G. lucidum* in *in vitro* model.

2. Materials and Methods

Collection of *Ganoderma lucidum*

The fruiting bodies of *G. lucidum* were collected from Mushroom Strengthening Center, Savar, Dhaka, Bangladesh. The *G. lucidum* was appropriately authenticated by a scientific officer at the National Mushroom Development and Extension Centre, Department of Agriculture Extension, Ministry of Agriculture, Sobhanbag, Savar, Dhaka, Bangladesh (Voucher number: NMDEC/2016/234).

Preparation of extract

The fruiting bodies were air-dried, milled by grinding using mortar and pestle. Subsequently, the coarse powder (300 gm) of *G. lucidum* was exposed to successive solvent extraction by soaking for 48 h using a solvent of 100% methanol. Filtered contents were distilled, evaporated, air-dried, and stored in air-tight plastic containers at 4°C until use [29].

Assay of free radical scavenging properties

The free radical scavenging activity of MEGL was determined by the 1,1-diphenyl-2-picrylhydrazyl (DPPH) assay, a method reported by Villano [30]. Herein, 200 μ L of MEGL extract was incubated with 3.8 mL DPPH solution in the dark at room temperature for 1 h. In this reaction, DPPH was reduced into yellow-colored and the intensity of color was read at 517 nm. Similarly, a control reaction was carried out without the MEGL. The DPPH radical scavenging activity of MEGL was expressed as the percentage of inhibition and value was calculated by the following formula:

$$\text{Inhibition (\%)} = (A_o - A_1) / A_o \times 100 .$$

A_o = Absorbance of control Butylated hydroxytoluene (BHT).

A_1 = Absorbance of the test sample (MEGL).

Assay of enzyme inhibitory activity

In vitro enzyme inhibitory activity of MEGL was examined by a slight modification of the Bernfeld method [31]. Acarbose as the positive control obtained by dissolving 50 mg in 50 ml of phosphate buffer and diluted to get the appropriate concentration of 31.25 μ g/mL, 62.5 μ g/mL, 125 μ g/mL, 250 μ g/mL, and 500 μ g/mL using a buffer. At the same time, MEGL was dissolved in a buffer to get the aforementioned concentrations.

In this experiment, extract and enzyme (α -amylase, Hi media Rm638) were mixed with 1:2 ratio. In brief, 100 μ L of MEGL was taken to react with 200 μ L of α -amylase and 100 μ L of 2 mM of phosphate buffer (pH-6.9). After 30 minutes of incubation, 100 μ L of 1% starch solution was added and kept this reaction mixture for 10 minutes.

Consequently, after 10 minutes, 500 μ L of dinitrosalicylic acid (DNS) reagent was added to test and control and kept in a boiling water bath for 5 minutes. Finally, absorbance was recorded at 540 nm using UV-vis spectrophotometer. The

percentage of inhibition of α -amylase enzyme was estimated using the following equation:

$$\text{Inhibition (\%)} = \left\{ \frac{(\text{control} - \text{test})}{\text{control}} \right\} \times 100.$$

Here, Control = Absorbance of Acarbose.

Test = Absorbance of MEGL.

Anti-*Staphylococcus aureus* activity

Anti-*Staphylococcus aureus* activity was investigated by the disc diffusion method [32]. *Staphylococcus aureus* (*S. aureus*), gram-positive bacteria obtained from the department of Biochemistry and Molecular Biology, Rajshahi University, Bangladesh. The strain was retained by periodic subculture on nutrient agar and well-kept-up at 4°C prior to use. In this experiment, Whatman No. 1 paper was used to make discs of 6 mm in diameter. The discs were then sterilized by autoclaving at 121°C for 20 minutes after which they were kept to stand for cooling. Stock solutions of MEGL were prepared by dissolving solid crude extract in DMSO. From this stock solution, nine (09) different concentrations of MEGL were prepared. These were 5, 10, 15, 20, 25, 30, 60, 120, and 240 mg/mL which finally yielded disc potencies of 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.6, 1.2, and 2.4 mg/disc respectively. Each disc was allowed to absorb the solution and kept for further analysis. Each paper disc was capable of absorbing 0.01 mL. Percentage (%) of zone of inhibition (ZOI) of MEGL against *S. aureus* was calculated using the following formula:

% Zone of inhibition

$$= \left\{ \frac{(\text{ZOI (mm) of control} - \text{ZOI (mm) of sample})}{\text{ZOI (mm) of control}} \right\} \times 100$$

3. Results

Free radical scavenging properties

Several concentrations of samples, ranging from 31.25 - 500 µg/ml of BHT and MEGL were tested for their antioxidant activities. It was observed that the test compound showed different antioxidant activity in different concentrations. From the given **Figure 1**, it was observed that the highest free radical scavenging activity was found at a higher concentration of BHT and MEGL. At 500 µg/ml, the BHT and MEGL showed approximate 95% and 94% of free radical scavenging activity respectively (shown in **Figure 1**).

Table 1 exhibits the effective concentrations of BHT and MEGL. It indicates that the EC₅₀ values of standard and *G. lucidum* extract, and predicted EC₈₀, EC₉₀, EC₉₅, and EC₉₉ values of BHT and mushroom extract, which calculated from each EC₅₀ value.

In **Table 1**, the EC₅₀ value of BHT was 16.2637 µg/mL while 22.1399 µg/mL was found for MEGL ($p < 0.05$). The predicted EC₉₀ values, which were calculated from EC₅₀ value, of BHT and MEGL were 1610.1063 µg/mL and 2191.8501 µg/mL correspondingly.

α -Amylase inhibitory activity

In this study, the α -amylase inhibitory activity of the methanolic extract of *G.*

lucidum was investigated. **Figure 2** illustrates the concentration-dependent of percent (%) of inhibition of α -amylase activity by methanolic extract of *G. lucidum*. The indicative results were found at a high concentration of MEGL. Acarbose (α -glucosidase inhibitor) was used as a standard.




Figure 1. Free radical scavenging activity of methanolic extract of *Ganoderma lucidum* (MEGL) and Butylated hydroxytoluene (BHT). “***” indicates the p-value of <0.001.




Figure 2. Doses-dependent amylase inhibitory activity of methanolic extract of *Ganoderma lucidum* (MEGL). Error bars were calculated at 95% confidence interval (CI).

Table 1. Effective concentrations of BHT and MEGL in µg/mL.

	EC ₅₀	EC ₇₀	EC ₈₀	EC ₉₀	EC ₉₅	EC ₉₉
BHT	16.2637	37.94863	65.0548	146.3733	309.0103	1610.1063
MEGL	22.1399*	51.65977	88.5596	199.2591	420.6581	2191.8501

Legends: BHT-Butylated hydroxytoluene, MEGL-Methanolic extract of *Ganoderma lucidum*. EC-Effective concentration. *p < 0.05.

At low concentration, 31.25 µg/mL acarbose showed around 9% more α -amylase inhibitory activity than that of MEGL, and their activities were steadily raised up and continued to increase about 88% and 81% for acarbose and MEGL respectively at 500 µg/mL. Non-significant column mean difference of percent inhibition was found in this experiment.

EC₅₀ values of Acarbose and MEGL are shown in **Table 2** and indicate the relative activity of acarbose and MEGL.

Anti-*Staphylococcus aureus* activity

The antibacterial activities of MEGL on *S. aureus* are shown in **Figure 3**. The range of 5 - 240 mg/ml MEGL was used to examine the inhibitory activity and 30 - 240 mg/ml were found to have the paramount inhibitory activity on *S. aureus*. We observed that the anti-*Staphylococcus aureus* activity of MEGL shows the different zone of inhibition in different concentrations. In case of very low concentration eg. 5 and 10 mg/ml of MEGL, no zone of inhibition was observed. The zone of inhibition gradually increased from 15 to 240 mg/ml.




Figure 3. Anti-*Staphylococcus aureus* activity of methanolic extract of *Ganoderma lucidum*. The activity was observed after 48 hrs of microbe inoculation. Error bars with 95% confidence interval (CI).

Table 2. Effective concentrations of acarbose and MEGL in µg/mL.

	EC ₅₀	EC ₇₀	EC ₈₀	EC ₉₀	EC ₉₅	EC ₉₉
Acarbose	14.4544	52.7259	90.4044	203.4099	429.4209	2237.509
MEGL	22.6011*	33.7269	57.8176	130.0896	274.6336	1430.986

Legends: MEGL-Methanolic extract of *Ganoderma lucidum*. EC-Effective concentration, *p < 0.05. The calculated EC₅₀ values of acarbose and MEGL were 14.4544 µg/mL and 22.6011 respectively. On the other hand, EC of 70, 80, 90, 95, and 99 values were computed from respective EC₅₀ values.

4. Discussion

In this study, DPPH reduction assay was used to investigate the free radical scavenging potentiality of mushroom extract, against positive control BHT. This DPPH reduction was dose-dependent action, and MEGL exhibited more significant free radical scavenging activity at high concentration (500 µg/mL). According to previous reports, polysaccharides and polysaccharide complexes isolated from various parts of mushrooms may attribute to the antioxidant activities of mushrooms. Antioxidant capacities of fungal polysaccharides may relate to the number of terminal hydroxyl groups and low molecular weight polysaccharides usually have higher antioxidant potentiality [33]. Several studies reported the radical scavenging potentiality of polysaccharides isolated from *G. lucidum* [34] [35] [36] [37]. According to Saltarelli *et al.*, the ethanolic extract of *G. lucidum* exhibited a signal-free radical scavenging activity. These findings show slightly higher DPPH radical scavenging activity which may be attributed to a strong proton donor [38]. Kang *et al.* reported the antioxidant potentiality of polysaccharide (EPS) of *G. lucidum* as H₂O₂ and DPPH scavenging activity. Isolated polysaccharides also showed strong reducing power and cellular protective effect on yeast cells from UV damage [39]. Wong *et al.* also reported the inhibitory effect of hot water extract *G. lucidum* on free radical generation in mice. This radical inhibitory effect is probably associated with the inhibition of lipid peroxidation and free radical scavenging capability of hot water extract of *G. lucidum* [40].

Diabetes mellitus is a chronic metabolic disorder which is associated with various types of health complications [41]. Several mechanisms are involved with the antidiabetic effects of herbal medicine like increases insulin secretion, act on pancreatic beta cells, or modify glucose absorption from the intestine. Mammalian α -amylase enzyme digests the starch into simple glucose in the intestine and facilitates their absorption into blood. Thus, inhibition of the α -amylase enzyme delays the glucose absorption and consequently reduces the postprandial blood glucose level [42]. Here, we investigated the α -amylase inhibitory activity of MEGL and result showed moderate inhibition of α -amylase enzyme compared to acarbose as standard. Ganoderic acids of *G. lucidum* may play an important role in the antidiabetic activities of this mushroom [43]. According to Islam S. *et al.* edible mushrooms showed in vitro and in vivo antidiabetic activity [44]. The fruiting body of *G. lucidum* has been known a natural remedy for the treatment of diabetes, cancer, hepatitis, and others [45] [46].

Anti-*S. aureus* activity of *G. lucidum* was investigated in this study with different concentrations (5 - 240 mg/mL). The mean zone of inhibition of methanolic extract was found at higher doses in the application. At 240 mg/mL dose of mushroom, approximate 25% of mean zone of inhibition was observed. This result consistent with previous studies where, aqueous and organic extracts (methanol, hexane, dichloromethane, ethyl acetate) of *G. lucidum* showed antimicrobial activity against a variety of bacterial strains such as *S. aureus*, *Escherichia*

coli, *Pseudomonas aeruginosa*, and *Enterobacter aerogenes* [47]. A study carried out by Heleno *et al.* and reported that methanolic extract of *G. lucidum* showed higher antibacterial activity against *S. aureus* and *Bacillus cereus* than streptomycin and ampicillin [48]. In 2015, Islam *et al.* have been demonstrated that *G. lucidum* showed potent antibacterial activity [49]. Kamara *et al.* also reported the antimicrobial activities of aqueous extract of *G. lucidum* against *Pseudomonas aeruginosa*, *Proteus vulgaris*, *Enterococcus faecalis*, *Salmonella typhimurium*, *Klebsiella pneumoniae*, *Streptococcus mutans*, and the *Bacillus subtilis* [50]. Although, the mechanisms of antimicrobial activities of *G. lucidum* are not clear but a mixture of compounds (polysaccharides, phenolic compounds, triterpenoids, glycosides, and tannins) may be responsible for the antibacterial activities of this mushroom [47].

In a summary, *G. lucidum* mushroom showed moderate radical scavenging, hypoglycemic and antibacterial activities. Thus, *G. lucidum* represents a high potential for searching new bioactive compounds for the treatment of various diseases.

5. Conclusion

This study indicates that the methanolic extract of *G. lucidum* has antioxidant, α -amylase inhibitory, and anti-*S. aureus* effects in *in vitro* model. Further *in vivo* studies are necessary to assess the above stated biological activities of *G. lucidum* which will be great benefits in treating oxidative stress, diabetes, and bacterial infections as a whole.

Acknowledgements

The authors are thankful to the department of Biochemistry and Molecular biology, Rajshahi University, Rajshahi, and department of Pharmacy, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh for their administrative assistance.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

- [1] Wasser, S.P. (2011) Current Findings, Future Trends, and Unsolved Problems in Studies of Medicinal Mushrooms. *Applied Microbiology and Biotechnology*, **89**, 1323-1332. <https://doi.org/10.1007/s00253-010-3067-4>
- [2] Lull, C., Wichers, H.J. and Savelkoul, H.F. (2005) Antiinflammatory and Immunomodulating Properties of Fungal Metabolites. *Mediators of Inflammation*, **2005**, Article ID: 892572. <https://doi.org/10.1155/MI.2005.63>
- [3] Watanabe, K., Afrin, R., Sreedhar, R., Karuppagounder, V., Harima, M., Alexander, X., *et al.* (2020) Pharmacological Investigation of *Ceraceomyces tessulatus* (Agaricomycetes) in Mice with Nonalcoholic Steatohepatitis. *International Journal of Me-*

- dicinal Mushrooms*, **22**, 683-692.
<https://doi.org/10.1615/IntJMedMushrooms.2020035048>
- [4] Waktola, G. and Temesgen, T. (2018) Application of Mushroom as Food and Medicine. *Advances in Biotechnology and Microbiology*, **11**, 97-101.
<https://doi.org/10.19080/AIBM.2018.11.555817>
- [5] Wasser, S.P. (2017) Medicinal Mushrooms in Human Clinical Studies. Part I. Anti-cancer, Oncoimmunological, and Immunomodulatory Activities. *International Journal of Medicinal Mushrooms*, **19**, 279-317.
<https://doi.org/10.1615/IntJMedMushrooms.v19.i4.10>
- [6] Wu, T. and Xu, B. (2015) Antidiabetic and Antioxidant Activities of Eight Medicinal Mushroom Species from China. *International Journal of Medicinal Mushrooms*, **17**, 129-140. <https://doi.org/10.1615/IntJMedMushrooms.v17.i2.40>
- [7] Cheung, P.C.K. (2008) Nutritional Value and Health Benefits of Mushrooms. In: Cheung, P.C.K., Ed., *Mushrooms as Functional Foods*, John Wiley & Sons, Inc., New York, NY, 71. <https://doi.org/10.1002/9780470367285.ch3>
- [8] Borchers A.T., Stern J.S., Hackman R.M, Keen C.L. and Gershwin M. E. (1999) Mushrooms, Tumors and Immunity. *Proceedings of the Society for Experimental Biology and Medicine*, **221**, 281-293.
- [9] Finimundy, T.C., Dillon, A.J.P., Henriques, J.A.P. and Ely, M.R. (2014) A Review on General Nutritional Compounds and Pharmacological Properties of the *Lentinula edodes* Mushroom. *Food and Nutrition Sciences*, **5**, 1095-1105.
<https://doi.org/10.4236/fns.2014.512119>
- [10] Koutrotsios, G., Kalogeropoulos, N., Stathopoulos, P., Kaliora, A.C. and Zervakis, G.I. (2017) Bioactive Compounds and Antioxidant Activity Exhibit High Intraspecific Variability in *Pleurotus Ostreatus* Mushrooms and Correlate Well with Cultivation Performance Parameters. *World Journal of Microbiology and Biotechnology*, **33**, Article No. 98. <https://doi.org/10.1007/s11274-017-2262-1>
- [11] Stamets, P. and Yao, C.D.W (2002) *My Comedicinals: An informational Treatise on Mushrooms*. MycoMedia Productions, Olympia, WA, 96.
- [12] Leskosek-Cukalovic, I., Despotovic, S., Lakic, N., Niksic, M., Nedovic, V. and Tesovic, V. (2010) *Ganoderma lucidum*—Medicinal Mushroom as a Raw Material for Beer with Enhanced Functional Properties. *Food Research International*, **43**, 2262-2269. <https://doi.org/10.1016/j.foodres.2010.07.014>
- [13] Sudheer, S., Alzorqi, I., Manickam, S. and Ali, A. (2018) Bioactive Compounds of the Wonder Medicinal Mushroom “*Ganoderma lucidum*”. In: Mérillon, J.M. and Ramawat, K.G., Eds., *Bioactive Molecules in Food*, Reference Series in Phytochemistry, Springer International Publishing AG, Switzerland, 1863-1893.
https://doi.org/10.1007/978-3-319-54528-8_45-1
- [14] Ekandjo, L.K. and Chimwamurombe, P.M. (2012) Traditional Medicinal Uses and Natural Hosts of the Genus *Ganoderma* in North-Eastern Parts of Namibia. *Journal of Pure and Applied Microbiology*, **6**, 1139-1146.
- [15] Bulam, S., Ustun, N.S. and Peksen, A. (2019) Health Benefits of *Ganoderma lucidum* as a Medicinal Mushroom. *Turkish Journal of Agriculture-Food Science and Technology*, **7**, 84-93. <https://doi.org/10.24925/turjaf.v7isp1.84-93.2728>
- [16] Martínez-Montemayor, M.M., Ling, T., Suárez-Arroyo, I.J., Ortiz-Soto, G., Santiago-Negron, C.L., Lacourt-Ventura, M., *et al.* (2019) Identification of Biologically Active *Ganoderma lucidum* Compounds and Synthesis of Improved Derivatives That Confer Anti-Cancer Activities *in Vitro*. *Frontiers in Pharmacology*, **10**, 115.
<https://doi.org/10.3389/fphar.2019.00115>
- [17] Sanodiya, B.S., Thakur, G.S., Baghel, R.K., Prasad, G.B.K.S. and Bisen, P.S. (2009)

- Ganoderma lucidum*: A Potent Pharmacological Macrofungus. *Current Pharmaceutical Biotechnology*, **10**, 717-742.
<https://doi.org/10.2174/138920109789978757>
- [18] Chang C.J., Lin C.S., Lu C.C., Martel, J., Ko, Y.F., Ojcius, D.M., *et al.* (2015) *Ganoderma lucidum* Reduces Obesity in Mice by Modulating the Composition of the Gut Microbiota. *Nature Communications*, **6**, 489.
- [19] Teng, B.S., Wang, C.D., Zhang, D., Wu, J.S., Pan, D., Pan, L.F., Yang, H.J. and Zhou, P. (2012) Hypoglycemic Effect and Mechanism of a Proteoglycan from *Ganoderma lucidum* on Streptozotocin-Induced Type 2 Diabetic Rats. *European Review for Medical and Pharmacological Sciences*, **16**, 166-175.
- [20] Liu, Y., Zhang, C., Du, J., Jia, R., Cao, L., Jeney, G., Teraoka, H., Xu, P. and Yin, G. (2017) Protective Effect of *Ganoderma lucidum* Polysaccharide against Carbon Tetrachloride-Induced Hepatic Damage in Precision-Cut Carp Liver Slices. *Fish Physiology and Biochemistry*, **43**, 1209-1221.
<https://doi.org/10.1007/s10695-016-0333-0>
- [21] Sun, X.Z., Liao, Y., Li, W. and Guo, L.M. (2017) Neuroprotective Effects of *Ganoderma lucidum* Polysaccharides against Oxidative Stress-Induced Neuronal Apoptosis. *Neural Regeneration Research*, **12**, 953-958.
<https://doi.org/10.4103/1673-5374.208590>
- [22] Li, F., Zhang, Y. and Zhong, Z. (2011) Antihyperglycemic Effect of *Ganoderma lucidum* Polysaccharides on Streptozotocin-induced Diabetic Mice. *International Journal of Molecular Sciences*, **12**, 6135-6145. <https://doi.org/10.3390/ijms12096135>
- [23] Lasukova, T.V., Maslov, L.N., Arbuzov, A.G., Burkova, V.N. and Inisheva, L.I. (2015) Cardioprotective Activity of *Ganoderma lucidum* Extract during Total Ischemia and Reperfusion of Isolated Heart. *Bulletin of Experimental Biology and Medicine*, **158**, 739-741. <https://doi.org/10.1007/s10517-015-2851-7>
- [24] Cheng, C.R., Yue, Q.X., Wu, Z.Y., Song, X.Y., Tao, S.J., Wu, X.H., *et al.* (2010) Cytotoxic Triterpenoids from *Ganoderma lucidum*. *Phytochemistry*, **71**, 1579-1585.
<https://doi.org/10.1016/j.phytochem.2010.06.005>
- [25] Lewis, K. (2017) New Approaches to Antimicrobial Discovery. *Biochemical Pharmacology*, **134**, 87-98. <https://doi.org/10.1016/j.bcp.2016.11.002>
- [26] Gharravi, A.M., Jafar, A., Ebrahimi, M., Mahmodi, A., Pourhashemi, E., Haseli, N., *et al.* (2018) Current Status of Stem Cell Therapy, Scaffolds for the Treatment of Diabetes Mellitus. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, **12**, 1133-1139. <https://doi.org/10.1016/j.dsx.2018.06.021>
- [27] Temple, N.J. (2000) Antioxidants and Disease: More Questions than Answers. *Nutrition Research*, **20**, 449-459. [https://doi.org/10.1016/S0271-5317\(00\)00138-X](https://doi.org/10.1016/S0271-5317(00)00138-X)
- [28] Wagner, J.R., Hu, C.C. and Ames, B.N. (1992) Endogenous Oxidative Damage of Deoxycytidine in DNA. *Proceedings of the National Academy of Sciences*, **89**, 3380-3384. <https://doi.org/10.1073/pnas.89.8.3380>
- [29] Harborne, A.J. (1998) *Phytochemical Methods a Guide to Modern Techniques of Plant Analysis*. Springer Science and Business Media, Berlin, Germany.
- [30] Villano, D., Fernandez-Pachon, M.S., Moya, M.L., Troncoso, A.M. and Garcia-Parrilla, M.C. (2007) Radical Scavenging Ability of Polyphenolic Compounds towards DPPH Free Radical. *Talanta*, **71**, 230-235.
<https://doi.org/10.1016/j.talanta.2006.03.050>
- [31] Bernfeld, P. (1955) Amylases, α and β . *Methods in Enzymology*, **1**, 149-158.
[https://doi.org/10.1016/0076-6879\(55\)01021-5](https://doi.org/10.1016/0076-6879(55)01021-5)
- [32] Bauer, A.W., Kirby, W.M., Sherris, J.C. and Turck, M. (1966) Antibiotic Suscepti-

- bility Testing by a Standardized Single Disk Method. *American Journal of Clinical Pathology*, **45**, 493-496. https://doi.org/10.1093/ajcp/45.4_ts.493
- [33] Wang, J., Hu, S., Nie, S., Yu, Q. and Xie, M. (2016) Reviews on Mechanisms of *in Vitro* Antioxidant Activity of Polysaccharides. *Oxidative Medicine and Cellular Longevity*, **2016**, Article ID: 5692852. <https://doi.org/10.1155/2016/5692852>
- [34] Kan, Y., Chen, T., Wu, Y., Wu, J. and Wu, J. (2015) Antioxidant Activity of Polysaccharide Extracted from *Ganoderma lucidum* Using Response Surface Methodology. *International Journal of Biological Macromolecules*, **72**, 151-157. <https://doi.org/10.1016/j.ijbiomac.2014.07.056>
- [35] Saltarelli, R., Palma, F., Gioacchini, A.M., Calcabrini, C., Mancini, U., De Bellis, R., et al. (2019) Phytochemical Composition, Antioxidant and Antiproliferative Activities and Effects on Nuclear DNA of Ethanolic Extract from an Italian Mycelial Isolate of *Ganoderma lucidum*. *Journal of Ethnopharmacology*, **231**, 464-473. <https://doi.org/10.1016/j.jep.2018.11.041>
- [36] Chen, X., Chen, Y., Li, S.B., Chen, Y.G., Lan, J.Y. and Liu, L.P. (2009) Free Radical Scavenging of *Ganoderma lucidum* Polysaccharides and Its Effect on Antioxidant Enzymes and Immunity Activities in Cervical Carcinoma Rats. *Carbohydrate Polymers*, **77**, 389-393. <https://doi.org/10.1016/j.carbpol.2009.01.009>
- [37] Yan, Z., Li, S., Yu, H. and Xin, X. (2019) Extraction and Antioxidant Activity of *Ganoderma lucidum* Polysaccharides Using Electrolyzed Oxidizing Water. *IOP Conference Series: Earth and Environmental Science*, **252**, Article No. 022074. <https://doi.org/10.1088/1755-1315/252/2/022074>
- [38] Saltarelli, R., Ceccaroli, P., Iotti, M., Zambonelli, A., Buffalini, M., Casadei, L., Valorani, L. and Stocchi, V. (2009) Biochemical Characterisation and Antioxidant Activity of Mycelium of *Ganoderma lucidum* from Central Italy. *Food Chemistry*, **116**, 143-151. <https://doi.org/10.1016/j.foodchem.2009.02.023>
- [39] Kang, Q., Chen, S., Li, S., Wang, B., Liu, X., Hao, L. and Lu, J. (2019) Comparison on Characterization and Antioxidant Activity of Polysaccharides from *Ganoderma lucidum* by Ultrasound and Conventional Extraction. *International Journal of Biological Macromolecules*, **124**, 1137-1144. <https://doi.org/10.1016/j.ijbiomac.2018.11.215>
- [40] Wong, K.L., Chao, H.H., Chan, P., Chang, L.P. and Liu, C.F. (2004) Antioxidant Activity of *Ganoderma lucidum* in Acute Ethanol-Induced Heart Toxicity. *Phytotherapy Research*, **18**, 1024-1026. <https://doi.org/10.1002/ptr.1557>
- [41] Qi, X.Y., Chen, W.J., Zhang, L.Q. and Xie, B.J. (2008) Mogrosides Extract from *Siraitia Grosvenori* Scavenges Free Radicals *in Vitro* and Lowers Oxidative Stress, Serum Glucose, and Lipid Levels in Alloxan-Induced Diabetic Mice. *Nutrition Research*, **28**, 278-284. <https://doi.org/10.1016/j.nutres.2008.02.008>
- [42] Karthic, K., Kirthiram, K.S., Sadasivam, S., Thayumanavan, B. and Palvannan, T. (2008) Identification of α Amylase Inhibitors from *Syzygium cumini* Linn Seeds. *Indian Journal of Experimental Biology*, **46**, 677-680.
- [43] Zhao, X.R., Huo, X.K., Dong, P.P., Wang, C., Huang, S.S., Zhang, B.J., Zhang, H.L., Deng, S., Liu, K.X. and Ma, X.C. (2015) Inhibitory Effects of Highly Oxygenated Lanostane Derivatives from the Fungus *Ganoderma lucidum* on P-Glycoprotein and A-Glucosidase. *Journal of Natural Products*, **78**, 1868-1876. <https://doi.org/10.1021/acs.jnatprod.5b00132>
- [44] Islam, S. and Pk, M.M.U. (2014) Antihyperglycemic Activity of Edible Mushroom, *Lentinus Edodes* in Alloxan Induced Diabetic Swiss Albino Mice. *International Journal of Pharmaceutical and Clinical Research*, **6**, 121-126.

- [45] Boh, B., Berovic, M., Zhang, J. and Lin, Z.-B. (2007) *Ganoderma lucidum* and Its Pharmaceutically Active Compounds. *Biotechnology Annual Review*, **13**, 265-301. [https://doi.org/10.1016/S1387-2656\(07\)13010-6](https://doi.org/10.1016/S1387-2656(07)13010-6)
- [46] Zhao, C., Fan, J., Liu, Y., Guo, W., Cao, H., Xiao, J., *et al.* (2019) Hepatoprotective activity of *Ganoderma lucidum* Triterpenoids in Alcohol-Induced Liver Injury in Mice, an iTRAQ-Based Proteomic Analysis. *Food Chemistry*, **271**, 148-156. <https://doi.org/10.1016/j.foodchem.2018.07.115>
- [47] Cor, D., Knez, Z. and Hrnčić, M.K. (2018) Antitumour, Antimicrobial, Antioxidant and Acetylcholinesterase Effect of *Ganoderma lucidum* Terpenoids and Polysaccharides: A Review. *Molecules*, **23**, 649. <https://doi.org/10.3390/molecules23030649>
- [48] Heleno, S.A., Ferreira, I.C.F.R., Esteves, A.P., Ciric, A., Glamoclija, J., Martins, A., *et al.* (2013) Antimicrobial and Demelanizing Activity of *Ganoderma lucidum* Extract, p-Hydroxybenzoic and Cinnamic Acids and Their Synthetic Acetylated Glucuronide Methyl Esters. *Food and Chemical Toxicology*, **58**, 95-100. <https://doi.org/10.1016/j.fct.2013.04.025>
- [49] Islam, M.R., Omar, M., Pk, M.M.U. and Mia, R. (2015) Phytochemicals and Antibacterial Activity Screening of Three Edible Mushrooms *Pleurotus Ostreatus*, *Ganoderma lucidum* and *Lentinula edodes* Accessible in Bangladesh. *American Journal of Biology and Life Sciences*, **3**, 31-35.
- [50] Kamra, A. and Bhatt, A.B. (2012) Evaluation of Antimicrobial and Antioxidant Activity of *Ganoderma lucidum* Extracts against Human Pathogenic Bacteria. *International Journal of Pharmacy and Pharmaceutical Sciences*, **2**, 359-362.

Abbreviations

BHT: Butylated hydroxytoluene

CI: Confidence Interval

DPPH: 1, 1-diphenyl-2-picrylhydrazyl

EC: Effective concentration

G. lucidum: *Ganoderma lucidum*

MEGL: Methanolic extract of *Ganoderma lucidum*

S. aureus: *Staphylococcus aureus*

ZoI: Zone of inhibition